Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + letrozole + trastuzumab + pertuzumab as neoadjuvant therapy for HR+/HER2+ stage II–III breast cancer
ChiCTR2200062114Phase 2Not yet recruiting
- Sponsor
- Chongqing Key Laboratory for Intelligent Oncology in Breast Cancer
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalpiciclib in breast cancer, sponsored by Chongqing Key Laboratory for Intelligent Oncology in Breast Cancer. Primary endpoint: Change in pathological Ki-67 proliferation index. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200062114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062114.